STOKE THERAPEUTICS INC

Stoke Therapeutics shares drop 3.5% to $25.70 after a Form 144 sale, highlighting potential dilution and capital infusion for its antisense‑oligonucleotide pipeline.

Stoke Therapeutics shares fall after SEC 144 filing, raising questions about liquidity, R&D and strategic direction in a volatile biotech market.